 eltrombopag |
| Promacta |
Pharmaceutical
company:
GlaxoSmithKline
www.gsk.com |
Pharmacologic classification: thrombopoietin receptor agonist
Therapeutic classification: platelet production stimulator
Pregnancy risk category: C
AVAILABLE FORMS
Tablets: 25 mg, 50 mg
INDICATIONS AND DOSAGES
Thrombocytopenia associated with chronic immune thrombocytopenic purpura when patient's response to corticosteroids, immunoglobulins, or splenectomy is inadequate—
Adults: 50 mg P.O. once daily.
ADJUST-A-DOSE: For patients of East Asian descent and those with moderate or severe hepatic impairment, reduce dose to 25 mg P.O. once daily.
CONTRAINDICATIONS AND CAUTIONS
None.
INTERACTIONS
Drug-drug.
Drugs that are substrates of OATP1B1 (rosuvastatin): May increase levels of these drugs. Reduce dose of these drugs.
Iron, calcium, aluminum, magnesium, selenium, zinc, and other polyvalent cations: May reduce eltrombopag absorption. Avoid using within 4 hours of each other.
ADVERSE REACTIONS
CNS: paresthesia.
EENT: cataract, conjunctival hemorrhage.
GI: dyspepsia, nausea, vomiting.
GU: menorrhagia.
Hematologic: thrombocytopenia.
Musculoskeletal: myalgia.
Skin: ecchymosis.
Reactions may be common, uncommon, life-threatening,
or COMMON AND LIFE-THREATENING.
|
